Drugmaker GlaxoSmithKline P.L.C. has agreed to pay $229 million to eight states to settle civil lawsuits related to the development and marketing of the diabetes drug Avandia and a separate suit by Louisiana related to other products.
Glaxo's headquarters is in London but it operates in Philadelphia and surrounding areas.
The company admitted no wrongdoing and disclosed the agreement in a filing with the Securities Exchange Commission.
Avandia was approved by the FDA to treat type 2 diabetes, but later faced greater restrictions because of reports that it caused increased risk of heart attacks.